Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

NCT06665178 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Sacituzumab Govitecan

Sponsor

British Columbia Cancer Agency

Collaborators

[object Object]